August 23rd 2023
At 85.3 months follow-up, the median overall survival with pembrolizumab was 32.7 months vs 15.9 months with ipilimumab.
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
2nd Annual International Congress on Pediatric Oncology
View More
Community Practice Connections™: 23rd Annual International Lung Cancer Congress®
View More
PER's Breast Cancer Symposia in San Antonio
Register Now!
2023 Friday Satellite Symposia: Preceding the 65th ASH Annual Meeting and Exposition
Register Now!
BURST CME™: Addressing Current Standards and Unmet Needs in Patients with Metastatic Breast Cancer
View More
20th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
9th Annual School of Gastrointestinal Oncology® (SOGO®)
Register Now!
New York GU 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Register Now!
BURST CME™: What Is the Real Risk in Lower-Risk MDS?
View More
BURST CME™: How Does Transfusion Burden Impact Real-World Outcomes in MDS?
View More
BURST CME™: Understanding Transfusion Dependence in Lower-Risk MDS
View More
The Latest on Acute Lymphocytic Leukemia
View More
A Focus on Acute Myeloid Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma
View More
Medical Crossfire®: Onco-Nursing Best Practices for Managing AEs Related to CAR T-Cell Therapy from Treatment Center to Community
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Medical Crossfire®: Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
25th Annual International Lung Cancer Congress®
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Community Practice Connections™: Multidisciplinary Strategies for Improving Outcomes in CML from Frontline Care… and Beyond!
View More
Crucial Conversations in R/R Multiple Myeloma: Nursing Strategies to Optimize Patient Communication and Improve Outcomes
View More
Advances In™: Aligning Pathology and Oncology Efforts in the Community to Improve NSCLC Care
View More
GlobaOncology Town Hall™: Primary Investigators Present Key Abstracts in the Management of B-Cell Lymphomas with BTK Inhibitors
View More
Myeloma Management Considerations: Applying the Evidence With Monoclonal Antibody Based Regimens
View More
FDA Follow-Up: Utilizing Relatlimab/Nivolumab in Clinical Practice for Metastatic Melanoma
March 25th 2022Oncology Nursing News® speaks with Hussein A. Tawbi, MD, PhD, principal investigator of the phase 2/3 RELATIVITY-046 trial, about the significance of the relatlimab/nivolumab approval for patients with unresectable or metastatic melanoma.
FDA Follow-Up: Utilizing Tebentafusp in Clinical Practice for Metastatic Uveal Melanoma
February 4th 2022Oncology Nursing News® meets with the lead investigator behind the phase 3 IMCgp100-202 trial to better understand the significance of tebentafusp’s approval and to determine what oncology nurses need to know about the new agent.
Pembrolizumab May Be Associated with Sustainable Relapse-Free Survival in High-Risk Melanoma
November 8th 2021After 6 months of additional follow-up, patients with resected high-risk stage II melanoma continued to experience improved relapse-free survival following treatment with adjuvant pembrolizumab.
Precision Medicine Highlights the Importance of Biomarkers in Melanoma
December 4th 2020With the identification of actionable alterations, precision medicine continues to lead the way in all areas of oncology, but especially in melanoma, according to Jason J. Luke, MD, FACP, who added that, in order to successfully apply personalized therapy, it’s critical to be fluent in the differences between biomarkers.
Tebentafusp Boosts Survival in Metastatic Uveal Melanoma
November 25th 2020Tebentafusp (IMCgp100) showed superiority in overall survival (OS) compared with investigator’s choice of therapy in patients with previously untreated metastatic uveal melanoma, according to results of a preplanned interim analysis of the phase 3 IMCgp100-202 trial (NCT03070392).
Cemiplimab Is Promising for Metastatic Basal Cell Carcinoma Treatment
November 18th 2020Cemiplimab (Libtayo) demonstrated clinically meaningful antitumor activity, including durable responses, and acceptable safety in patients with metastatic basal cell carcinoma (mBCC) after progression on or intolerance to hedgehog inhibitors.
Cabozantinib Plus Pembrolizumab May Improve Melanoma Outcomes
November 13th 2020In an effort to further improve outcomes without sacrificing tolerability, the combination of cabozantinib (Cabometyx) with pembrolizumab (Keytruda) is being evaluated in patients with advanced melanoma in a phase 1b/2 study (NCT03957551), according to a virtual presentation during the 2020 SITC Annual Meeting.
Predicting Immunotherapy Response in Melanoma
November 11th 2020Subgroup analyses from the phase III CheckMate-067 trial identified potential biomarkers in patients who achieved a complete response (CR) with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) but later progressed, according to Georgina V. Long, BSc, PhD, MBBS, FRACP.1 Now, investigators are working to answer more questions about this group of patients.